FY2024 Earnings Estimate for CNTB Issued By Leerink Partnrs

Connect Biopharma Holdings Limited (NASDAQ:CNTB) – Equities research analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Connect Biopharma in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($0.23) for the year. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.20) per share. Leerink Partnrs also issued estimates for Connect Biopharma’s FY2025 earnings at ($0.65) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.10) EPS and FY2028 earnings at ($0.49) EPS.

Connect Biopharma Price Performance

CNTB opened at $0.92 on Monday. The business has a 50 day moving average of $1.07 and a 200-day moving average of $1.15. Connect Biopharma has a 1-year low of $0.91 and a 1-year high of $2.66.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CNTB. Catalina Capital Group LLC bought a new position in Connect Biopharma during the fourth quarter valued at about $66,000. Callan Capital LLC grew its holdings in shares of Connect Biopharma by 91.3% during the 4th quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock worth $110,000 after purchasing an additional 38,177 shares in the last quarter. Choreo LLC bought a new stake in shares of Connect Biopharma during the fourth quarter valued at approximately $204,000. Finally, BML Capital Management LLC increased its position in shares of Connect Biopharma by 2.4% during the third quarter. BML Capital Management LLC now owns 2,093,232 shares of the company’s stock valued at $3,014,000 after purchasing an additional 49,984 shares during the period. Institutional investors and hedge funds own 58.72% of the company’s stock.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.